Researchers have found a protein by which doctors can monitor the likelihood of high risk pregnancies.
PROBLEM: It's long been clear that a causal relationship exists between the malnourishment of a fetus and the birth of a stillborn or an alarmingly small infant. But the ability to predict the likeliness of these complications has been minimal.
- Keep Your Commute to Less Than 15 Miles (or Else)
- Social Inequality Has Been Around Since the Stone Age
METHODOLOGY: Led by Doctor Andrée Gruslin, researchers from the Ottawa Hospital Research Institute and the University of Ottawa examined first trimester blood samples from women who had participated in a large study of pregnancies entitled the Ottawa and Kingston birth cohort. 72 women -- half with very small babies and half with average weight babies -- were included in the study.
RESULTS: The researchers found that women with elevated levels of the protein Insulin Growth Factor Binding Protein 4 (IGFBP-4) were 22 times more likely to produce tiny babies than women who maintained normal IGFBP-4 levels.
CONCLUSION: Gruslin suggests that Insulin Growth Factor Binding Protein 4 inhibits an essential placental growth hormone, IGF-II, resulting in a malnourished and underdeveloped placenta and fetus. High levels of IGFBP-4 can therefore lead to serious health complications in pregnancy, such as stillbirths and precariously underweight babies.
IMPLICATION: The researchers intend to refine the IGFBP-4 blood test in order to make it available to the public. Gruslin also hopes to develop a method by which to target the IGFBP-4 protein, which could effectively reduce the occurrences of stillbirths, fetal growth restriction, and adulthood chronic diseases such as diabetes and hypo-tension that accompany this latter condition.
SOURCE: The full study, "Significance of IGFBP-4 in the development of fetal growth restriction," is published in the Journal of Clinical Endocrinology and Metabolism.
We want to hear what you think about this article. Submit a letter to the editor or write to email@example.com.